Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show.

Welcome to Helix Talk, episode 56. I'm your co-host, Dr. Kane. And I'm Dr. Patel. And today, actually, we're going to talk about a very interesting topic of biosimilars.

We're going to call it entering the era of biosimilars.

So before we get into biosimilars, I think we really have to talk about, you know,

what are some of the definitions that surround the topic of a biosimilar?

So biologics is probably the first thing that we have to talk about.

Right.

And those were the agents that came out in the market first.

And biosimilars, as the name sounds, they're similar to these biologic agents.

So, yes, I totally agree we need to understand what the biologics are.

And these biologic drugs or agents are basically, as the name

suggests, are created biologically. They're very complex molecules, and so per batch, there could be

variation in the molecule size or shape in itself. When you describe it as biologically produced or

created, we're talking like bacteria with recombinant DNA technology where the bacteria themselves

or some organism is producing these complex, typically protein-oriented molecules.

So it's not like some kind of test tube is creating a chemical reaction.

It's literally a DNA molecule that's given to a bacteria to make the thing that we're wanting,

which we call a biologic.

...